

## Quantitative Analysis of Adalimumab (Humira®) and Anti-Adalimumab Antibodies

(LS-021/023)

PRESCRIBER INFORMATION	PATIENT INFORMATION
Last Name: _____ First Name: _____ Clinic: _____ Address: _____ <small>No Street Office</small> _____ <small>City Prov. Postal code</small> Tel: _____ Fax: _____ Licence No. _____ Signature: <b>X</b> _____ <small>Date (YYYY/MM/DD)</small>	Last Name: _____ First Name: _____ Sex: <input type="checkbox"/> F <input type="checkbox"/> M Date of Birth: _____ <small>Year / Month / Day</small> Address: _____ <small>No Street Apt</small> _____ <small>City Prov. Postal code</small> Tel (home): _____ Tel (daytime): _____ Date of next injection: _____ <small>Year / Month / Day</small>
SAMPLE COLLECTION	SPECIMEN
Collection Date: _____ / _____ / _____ <small>Year Month Day</small> Collection Centre: _____	<p><b>Serum: 1 mL</b></p> <p>For optimal results, sample collection should be within 24-48 hours prior to the next Humira injection.</p>
RESULTS TRANSMISSION	
<p>Results will be provided within 5 working days following receipt by the laboratory for the quantitative analysis of Adalimumab. When the Adalimumab level result is negative, the quantitative analysis of anti-Adalimumab antibodies will be performed on the same sample. These results will be reported within 10 work days from the time we received the sample.</p> <p>Please note that the prescriber can access patient results online. To request web access, please contact our Customer Care department.</p>	
FOR INTERNAL USE ONLY	
Comments: _____ _____ _____	

This analysis is supported by an unrestricted grant provided by Abbvie for patients with Crohn's disease.